Press release
Celiac Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Celiac Disease Pipeline Drugs
Celiac Disease is a genetic autoimmune disease. It is caused due to the consumption of protein called gluten, which is found in barley, wheat, and rye. It enables damage the finger-like villi of small intestine and body will be unable to absorb nutrients into the bloodstream that leads to malnutrition. Symptoms of celiac disease include food allergy, watery and itchy eyes, difficulty in breathing, nausea, abdominal pain, mouth ulcers.
Celiac disease is diagnosed by serology tests and genetic tests. Treatment includes strict gluten-free diet. There are no FDA approved drugs to treat celiac disease.
A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx
Segmentation:
By Drugs, Celiac Disease pipeline drugs are segmented as:
• Larazotide
• Pancrelipase
• Rifaximin
• Triamcinolone
• Bupivacaine
By Route of Administration, Celiac Disease pipeline drugs are segmented as:
• Oral
• Parenteral
By Trial Phase, Celiac Disease pipeline drugs are segmented as:
• Preclinical
• Phase 1
• Phase 2
• Phase 3
• Phase 4
By Company, Celiac Disease pipeline drugs are segmented as:
• AMYRA Biotech AG (Switzerland)
• Avaxia Biologics, Inc. (U.S.)
• Calypso Biotech SA (Switzerland)
• Provid Pharmaceuticals Inc. (U.S.)
• Sitari Pharmaceuticals (U.S.)
• Cour Pharmaceuticals (U.S.)
• Glenmark Pharmaceuticals Ltd. (India)
• Innovate Biopharmaceuticals (U.S.)
• Others
To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu
Space Analysis:
• In November 2017, ImmusanT, Inc.raised $40 million Series C equity financing from ARCH Venture Partners and Vatera Healthcare Partners to proceed Phase II clinical trial of escalating doses of Nexvax2 in celiac patients who possess the human leukocyte antigen DQ2.5 (HLA-DQ2.5) immune recognition gene.
• In February 2016, Innovate Biopharmaceuticals Inc., completed an agreement to license Alba Therapeutics assets relating to larazotide acetate, a tight junction regulator, progressing toward Phase 3 clinical trials for the treatment of celiac disease.
• In December 2015, Takeda Pharmaceutical Company Limited and Cour Pharmaceutical Development Company, Inc. entered into a partnership to research and develop novel immune modulating therapies for the potential treatment of celiac disease
• In March 2015, Falk Pharma and Zedira entered into a collaboration to perform Phase 1 clinical trials of ED1227, a direct-acting inhibitor of tissue transglutaminase. The small molecule targets the dysregulated transglutaminase within the small intestine in order to dampen the immune response to gluten which drives the celiac disease process.
Report Description:
Celiac Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Celiac Disease treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Celiac Disease pipeline drugs development. This report studies the dynamics of the Celiac Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Celiac Disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3
Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on each drug candidates in the clinical trial phases
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/celiac-disease-pipeline-drugs-assessment/
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Email: sales@precisionbusinessinsights.com
Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Celiac Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 here
News-ID: 1049123 • Views: …
More Releases from Precision Business Insights
Gaming Controller Market Rising Demand for Gaming Stations and eSports
According to the Precision Business Insights (PBI), latest report the gaming controller market size was valued at USD 2,382.1 million in 2023, growing at an 8.5% CAGR from 2024 to 2030. The key drivers of the expansion of the global gaming controller include the enhanced gaming experience, technology advancements, consumer preferences and ergonomics, competitive gaming and esports, intuitiveness, and portability of the gaming controllers.
View Full Report: https://www.precisionbusinessinsights.com/market-reports/gaming-controller-market …
Next Generation Dietary Supplements Market Size, Growth Opportunities 2024-2030
According to Precision Business Insights (PBI), the latest report, the global next-generation dietary supplements market was valued at USD 10,752.3 million in 2023 and is expected to grow at a CAGR of 8.8% from 2024-2030. The primary factors that drive the market are the growing demand for rising consumer knowledge of the various health benefits of Next Generation Dietary Supplements, as well as rising disposable income levels, fuel market expansion…
Catamaran Market Increasing Popularity Of Water Sports And Fishing Activities
According to Precision Business Insights (PBI), the latest report, the catamaran market is valued at USD 1,635.7 million in 2023 and is anticipated to grow a CAGR of 4.9% over the forecast period. The primary factors that drive the market are the growing demand for Catamaran pushes the market to enhance efficiency, minimize time consumption, and reduce post-harvest operating losses. Catamaran are good solutions for reducing high labour costs since…
Refrigerated Display Cases Market Size, Share, Growth Trends and Forecast 2024-2 …
According to Precision Business Insights (PBI), latest report, the refrigerated display cases market was valued at USD 8,248.5 million in 2023 and is expected to grow at a 5.1% CAGR from 2024 to 2030. The primary drivers of the expansion of the global refrigerated display cases market include the increasing demand for frozen food and drinks among urban consumers. In addition, growing awareness about environment sustainability and energy efficiency is…
More Releases for Celiac
Celiac Disease Market Know the Scope and Trends
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Celiac Disease Market Size, Share & Trends Analysis Report By Treatments (Infliximab, Larazotide Acetate, Gluten Free Diet), Route Of Administration (Oral And Parenteral), End-Users (Hospitals, Homecare), And Distribution Channels (Hospital Pharmacy, Online Pharmacy, And Retail Pharmacy), Region, Market Outlook And Industry Analysis 2031"
The Global Celiac Disease Market is estimated to reach over USD 1,195.5 Mn…
Celiac Disease Market Revenue Report with Forecast to 2031
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Celiac Disease Market Size, Share & Trends Analysis Report By Treatments (Infliximab, Larazotide Acetate, Gluten Free Diet), Route Of Administration (Oral And Parenteral), End-Users (Hospitals, Homecare), And Distribution Channels (Hospital Pharmacy, Online Pharmacy, And Retail Pharmacy), Region, Market Outlook And Industry Analysis 2031"
The Global Celiac Disease Market is estimated to reach over USD 1,195.5 Mn…
Celiac Disease Treatment Market
Celiac disease is an autoimmune disorder that affects the small intestine, triggered by the ingestion of gluten-a protein found in wheat, barley, and rye. This condition leads to inflammation and damage in the intestinal lining, which can hinder nutrient absorption and result in various gastrointestinal and systemic symptoms. As awareness of celiac disease grows, so does the demand for effective treatments and dietary solutions. This post delves into the celiac…
Celiac Disease Drugs Market to Record an Exponential CAGR
Celiac Disease Drugs Market report analyses the prospects in the market for several shareholders and aspirants by identifying the high-growth segments, main actions approved by them and Celiac Disease Drugs market recent progressions. The Celiac Disease Drugs market report is prepared after fundamental levels of research regarding the Celiac Disease Drugs Industry.
Celiac Disease Drugs Market by Drugs (First Line of Treatment and Second Line of Treatment) - Global Opportunity Analysis…
Celiac disease Market to Observe Strong Development by 2025
The global Celiac Disease Market is prophesied to rake in a heavy demand on account of three decisive factors such as healthy government initiatives, prevalence of the disease, and increased consumption of foods containing gluten.
Governments of different countries such as the U.K., Canada, New Zealand, Australia, and Argentina and the European Union are expected to accelerative initiatives for the treatment of celiac disease. These governments could provide a strong boost…
Celiac disease market: Global Trends and Forecast Analysis 2025
Celiac disease is an autoimmune disorder in which the surface of the small intestine is damaged by a protein called gluten. Gluten is found in rye, barley, and wheat. Gluten triggers an immune reaction in the small intestine damaging the villi (small finger-like projections in the small intestine which promote absorption). The damage restricts the ability of the body to absorb proteins, nutrients, fats, vitamins, carbohydrates, and minerals. Eventually, this…
